The role of frontline autologous stem cell transplantation for primary plasma cell leukemia: a retrospective multicenter study (KMM160)

• Published in: Oncotarget 2017-10, Vol.8 (45), p.79517-79526
• Main Authors: Jung, Sung-Hoon, Lee, Je-Jung, Kim, Kihyun, Suh, Cheolwon, Yoon, Dok Hyun, Min, Chang-Ki, Sohn, Sang Kyun, Choi, Chul Won, Lee, Ho Sup, Kim, Hyo Jung, Shin, Ho-Jin, Bang, Soo-Mee, Yoon, Sung-Soo, Park, Seong Kyu, Yhim, Ho-Young, Kim, Min Kyoung, Jo, Jae-Cheol, Mun, Yeung-Chul, Lee, Jae Hoon, Kim, Jin Seok
• Format: Article
• Language: English
• Subjects: Clinical Research Paper
• ISSN: 1949-2553; 1949-2553
• DOI: 10.18632/oncotarget.18535

Primary plasma cell leukemia (pPCL) is a rare and aggressive plasma cell neoplasm, with rapidly progressing clinical course. We evaluated the treatment status and survival outcomes of 69 Korean patients with pPCL. Of them, 59 patients were treated; 15 (25.4%) were treated initially with novel agent-based regimens with upfront autologous stem cell transplantation (ASCT), 7 (11.9%) with conventional chemotherapy with upfront ASCT, 21 (35.6%) with novel agent-based regimens only, and 16 (27.1%) were treated with conventional chemotherapy alone. Overall response rates after initial therapy were significantly higher in patients treated with novel agent-based regimens compared with those treated with conventional chemotherapies (75% vs. 43.4%, 0.026). Median progression-free survival (PFS) and overall survival (OS) were 12.2 months and 16.1 months, respectively. The median PFS of the four treatment groups-conventional chemotherapy alone, novel agents alone, conventional chemotherapy with ASCT, and novel agents with ASCT-were 1.2, 9.0, 10.5, and 26.4 months, respectively ( < 0.001); the median OS of the four treatment groups were 2.9, 12.3, 14.1, and 31.1 months, respectively ( < 0.001). The median OS was also significantly better in the patients with novel agents with ASCT versus other patients. In a multivariate analysis, an increased lactate dehydrogenase level, low albumin (< 3.5 g/dL), and non-CR after front-line treatment were independently associated with poor PFS and OS. In conclusion, the use of novel agent-based therapy with ASCT and achieving a deep response to front-line treatment are important in expecting improved PFS and OS in patients with pPCL.